钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂在射血分数降低或保留的心力衰竭患者中是否具有相似的心血管获益？
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
机构信息
Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India.
Department of Diabetes, Fortis-CDOC hospital for Diabetes & Allied Science, New Delhi, India.
出版信息
J Diabetes. 2021 Jul;13(7):596-600. doi: 10.1111/1753-0407.13182. Epub 2021 Apr 21.
Highlights The beneficial cardiovascular (CV) effects of SGLT-2 inhibitors (SGLT-2i) in patients with heart failure are already known. Whether SGLT-2i exert similar CV effects in heart failure with reduced or preserved ejection fraction is not known. This meta-analysis showed SGLT-2i exert similar CV benefits irrespective of the types of heart failure. Future trials will confirm or refute the CV effects of SGLT-2i in patients with heart failure with preserved ejection fraction.
要点 SGLT-2 抑制剂（SGLT-2i）对心力衰竭患者的心血管（CV）有益作用已为人所知。但 SGLT-2i 是否对射血分数降低或保留的心衰患者有类似的 CV 作用尚不清楚。本荟萃分析表明，SGLT-2i 发挥了相似的 CV 获益，而与心力衰竭的类型无关。未来的试验将证实或反驳 SGLT-2i 在射血分数保留的心衰患者中的 CV 作用。
Zotero 插件